CSL Behring's Monthly HAE Biologic Reshapes Rare Disease Supply Chain

CSL Behring's FDA approval of ANDEMBRY (garadacimab) for hereditary angioedema prevention introduces a once-monthly subcutaneous biologic into a rare disease category where dosing frequency and cold-chain integrity directly shape patient adherence and distributor network design. For QA directors and supply chain leads, the June 17, 2025 approval signals a new set of biologics handling requirements that will need to be embedded into existing rare disease distribution frameworks.

ANDEMBRY is indicated for prevention of HAE attacks in patients 12 years and older, administered as a 200 mg subcutaneous injection once monthly. HAE is a rare hereditary condition characterized by recurrent episodes of swelling affecting the skin, airway, throat, and gastrointestinal tract. The monthly dosing interval, while patient-friendly, places specific demands on cold-chain logistics and site-of-care dispensing models that manufacturers and specialty pharmacies will need to address under current GMP expectations.

The Phase 3 trial supporting approval was a six-month, randomized, double-blind, placebo-controlled, parallel-group study enrolling 64 patients across 28 centers in seven countries: Canada, Germany, Hungary, Israel, Japan, the Netherlands, and the United States. Patients were randomized 1:1 to ANDEMBRY or placebo following a two-month run-in period requiring documentation of two or more acute HAE attacks. The primary endpoint was the time-normalized number of investigator-confirmed HAE attacks per month over the six-month treatment period. Approximately 33% of trial participants were from the United States.

The multinational trial footprint, spanning seven countries and 28 sites, reflects the enrollment challenges inherent to ultra-rare disease programs and will inform how CSL Behring structures its post-approval pharmacovigilance and real-world evidence collection obligations. For regulatory affairs teams benchmarking rare disease development programs, the trial's eligibility criteria, including the run-in attack frequency requirement, represent a design consideration with direct implications for patient identification and site qualification strategies.

Source: FDA Drug Trials Snapshots: ANDEMBRY, original approval date June 17, 2025. Full prescribing information and approved conditions of use are available via the ANDEMBRY Prescribing Information document.